Table 3.
Clinicopathological data of the patients in NCHT-preferable and NHT-preferable groups.
| Overall (n = 64) |
NCHT-preferable (n = 37) |
NHT-preferable (n = 27) |
p | |
|---|---|---|---|---|
| Treatment | ||||
| NCHT | 32 (50.00%) | 25 (67.57%) | 7 (25.93%) | 0.002 (fisher.test) |
| NHT | 32 (50.00%) | 12 (32.43%) | 20 (74.07%) | |
| Age | ||||
| Mean(SD) | 67.88 (5.44) | 67.27 (5.85) | 68.7 (4.81) | 0.337 (wilcox.test) |
| median[IQR] | 68.00 [64.00, 71.25] | 67.00 [63.00, 71.00] | 68.00 [66.00, 72.50] | |
| Initial PSA | ||||
| 0-10 ng/ml | 2 (3.12%) | 1 (2.70%) | 1 (3.70%) | 0.513 (fisher.test) |
| 10-20 ng/ml | 2 (3.12%) | 2 (5.41%) | 0 (0.00%) | |
| 20-100 ng/ml | 32 (50.00%) | 16 (43.24%) | 16 (59.26%) | |
| >100 ng/ml | 28 (43.75%) | 18 (48.65%) | 10 (37.04%) | |
| Preoperative PSA | ||||
| 0-10 ng/ml | 59 (92.19%) | 35 (94.59%) | 24 (88.89%) | 0.386 (fisher.test) |
| 10-20 ng/ml | 3 (4.69%) | 1 (2.70%) | 2 (7.41%) | |
| 20-100 ng/ml | 1 (1.56%) | 0 (0.00%) | 1 (3.70%) | |
| Missing | 1 (1.56%) | 1 (2.70%) | 0 (0.00%) | |
| Postoperative PSA | ||||
| 0-10 ng/ml | 59 (92.19%) | 35 (94.59%) | 24 (88.89%) | 0.515 (fisher.test) |
| 20-100 ng/ml | 2 (3.12%) | 2 (5.41%) | 0 (0.00%) | |
| Missing | 3 (4.69%) | 0 (0.00%) | 3 (11.11%) | |
| Gleason score | ||||
| < 8 | 23 (35.94%) | 16 (43.24%) | 7 (25.93%) | 0.192 (fisher.test) |
| ≥ 8 | 41 (64.06%) | 21 (56.76%) | 20 (74.07%) | |
| T stage | ||||
| T2c | 3 (4.69%) | 1 (2.70%) | 2 (7.41%) | 0.761 (fisher.test) |
| T3a | 21 (32.81%) | 11 (29.73%) | 10 (37.04%) | |
| T3b | 21 (32.81%) | 13 (35.14%) | 8 (29.63%) | |
| T4 | 19 (29.69%) | 12 (32.43%) | 7 (25.93%) | |
| N stage | ||||
| N0 | 32 (50.00%) | 16 (43.24%) | 16 (59.26%) | 0.311 (fisher.test) |
| N1 | 32 (50.00%) | 21 (56.76%) | 11 (40.74%) | |